HSS Journal ®

, Volume 9, Issue 2, pp 166–170 | Cite as

Use of Imatinib in the Prevention of Heterotopic Ossification

  • Clément M. L. Werner
  • Stefan M. Zimmermann
  • Carola C. Würgler-Hauri
  • Joseph M. Lane
  • Guido A. Wanner
  • Hans-Peter Simmen
Original Article

Abstract

Background

Heterotopic ossification (HO) is a common complication following orthopedic and trauma surgery, which may have substantial negative effects on the postoperative outcome. Angiogenesis appears to play a critical role in heterotopic ossification. One of the involved signaling molecules is platelet-derived growth factor (PDGF) which may be inhibited by imatinib.

Questions/Purposes

Our goal was to prevent HO by pharmacologically interfering with the molecular signaling pathways involved in the developmental process. We hypothesized that by administering a proven inhibitor of PDGF expression, heterotopic bone formation may be prevented.

Methods

The effect of imatinib on HO formation was studied in a murine model which reliably produces islets of HO within the soft tissue following Achilles tenotomy. The control group underwent Achilles tenotomy only. The imatinib group received imatinib mesylate. After trial completion, the limbs were harvested and scanned by micro-CT. Heterotopic bone volume was then identified and quantified.

Results

The mean volume of heterotopic bone formed in the control group was 0.976mm3 compared to 0.221 mm3 in the imatinib group. The volume of HO in the treatment group was reduced by 85% compared to the control group.

Conclusions

The administration of imatinib was associated with a significantly reduced volume of HO. This may be due to the inhibitory effect of imatinib on the PDGF signaling pathway during development of HO.

Clinical Relevance

The successful reduction of HO formation following imatinib administration has led to further insight concerning the pathogenesis of HO which in the future may lead to new clinical approaches towards the prevention of HO.

Keywords

heterotopic ossification prevention imatinib mesylate murine PDGF 

Supplementary material

11420_2013_9335_MOESM1_ESM.pdf (344 kb)
ESM1(PDF 344 kb)

References

  1. 1.
    Alini M, Marriott A, Chen T, et al. A novel angiogenic molecule produced at the time of chondrocyte hypertrophy during endochondral bone formation. Dev Biol. 1996;176:124-132.PubMedCrossRefGoogle Scholar
  2. 2.
    Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med. 2006;354:2006-2013.PubMedCrossRefGoogle Scholar
  3. 3.
    Deckers M, Karperien M, van der Bent C, et al. Expression of vascular endothelial growth factors and their receptors during osteoblast differentiation. Endocrinology. 2000;141:1667-1674.PubMedCrossRefGoogle Scholar
  4. 4.
    Dewar AL, Farrugia AN, Condina MR, et al. Imatinib as a potential antiresorptive therapy for bone disease. Blood. 2006;107:4334-4337.PubMedCrossRefGoogle Scholar
  5. 5.
    Fitter S, Dewar AL, Kostakis P, et al. Long-term imatinib therapy promotes bone formation in CML patients. Blood. 2008;111:2538-2547.PubMedCrossRefGoogle Scholar
  6. 6.
    Flecknell PA. Laboratory Animal Anesthesia. London: Academic Press (Elsevier); 1996.Google Scholar
  7. 7.
    Garland D. A clinical perspective on common forms of acquired heterotopic ossification. Clin Orthop Relat Res. 1991;13–29;Google Scholar
  8. 8.
    Goodman S, Ma T, Genovese M, et al. COX-2 selective inhibitors and bone. Int J Immunopathol Pharmacol. 2003;16:201-205.PubMedGoogle Scholar
  9. 9.
    Goodman S, Ma T, Trindade M, et al. COX-2 selective NSAID decreases bone ingrowth in vivo. J Orthop Res. 2002;20:1164-1169.PubMedCrossRefGoogle Scholar
  10. 10.
    Jönsson S, Olsson B, Ohlsson C, et al. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica. 2008;93:1101-1103.PubMedCrossRefGoogle Scholar
  11. 11.
    McClure J. The effect of diphosphonates on heterotopic ossification in regenerating Achilles tendon of the mouse. J Pathol. 1983;139:419-430.PubMedCrossRefGoogle Scholar
  12. 12.
    Naraghi F, DeCoster T, Moneim M, et al. Heterotopic ossification. Orthopedics. 1996;19:145-151.PubMedGoogle Scholar
  13. 13.
    Nash TJ, Howlett CR, Martin C, et al. Effect of platelet-derived growth factor on tibial osteotomies in rabbits. Bone. 1994;15:203-208.PubMedCrossRefGoogle Scholar
  14. 14.
    O'Sullivan S, Horne A, Wattie D, et al. Decreased bone turnover despite persistent secondary hyperparathyroidism during prolonged treatment with imatinib. J Clin Endocrinol Metab. 2009;94:1131-1136.PubMedCrossRefGoogle Scholar
  15. 15.
    Puzas JE, Miller MD, Rosier RN. Pathologic bone formation. Clin Orthop. 1989;245:269-281.PubMedGoogle Scholar
  16. 16.
    Ranly DM, McMillan J, Keller T, et al. Platelet-derived growth factor inhibits demineralized bone matrix-induced intramuscular cartilage and bone formation. A study of immunocompromised mice. J Bone Joint Surg Am. 2005;87:2052-2064.PubMedCrossRefGoogle Scholar
  17. 17.
    Roussy Y, Bertrand Duchesne MP, Gagnon G. Activation of human platelet-rich plasmas: effect on growth factors release, cell division and in vivo bone formation. Clin Oral Implants Res. 2007;18:639-648.PubMedCrossRefGoogle Scholar
  18. 18.
    Saudan M, Saudan P, Perneger T, et al. Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomised trial. J Bone Joint Surg Br. 2007;89:155-159.PubMedCrossRefGoogle Scholar
  19. 19.
    van Steensel L, Paridaens D, Schrijver B, et al. Imatinib mesylate and AMN107 inhibit PDGF-signaling in orbital fibroblasts: a potential treatment for Graves' ophthalmopathy. Invest Ophthalmol Vis Sci. 2009;50:3091-3098.PubMedCrossRefGoogle Scholar
  20. 20.
    Vandyke K, Dewar AL, Diamond P, et al. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo. J Bone Miner Res. 2010;25:1759-1770.PubMedCrossRefGoogle Scholar
  21. 21.
    Vandyke K, Fitter S, Dewar AL, et al. Dysregulation of bone remodeling by imatinib mesylate. Blood. 2010;115:766-774.PubMedCrossRefGoogle Scholar
  22. 22.
    Vuorinen K, Gao F, Oury TD, et al. Imatinib mesylate inhibits fibrogenesis in asbestos-induced interstitial pneumonia. Exp Lung Res. 2007;33:357-373.PubMedCrossRefGoogle Scholar
  23. 23.
    Yin M, Gentili C, Koyama E, et al. Antiangiogenic treatment delays chondrocyte maturation and bone formation during limb skeletogenesis. J Bone Miner Res. 2002;17:56-65.PubMedCrossRefGoogle Scholar

Copyright information

© Hospital for Special Surgery 2013

Authors and Affiliations

  • Clément M. L. Werner
    • 1
    • 3
  • Stefan M. Zimmermann
    • 1
  • Carola C. Würgler-Hauri
    • 1
  • Joseph M. Lane
    • 2
  • Guido A. Wanner
    • 1
  • Hans-Peter Simmen
    • 1
  1. 1.Department of TraumatologyUniversity HospitalZurichSwitzerland
  2. 2.Hospital for Special SurgeryNew YorkUSA
  3. 3.Klinik für UnfallchirurgieUniversitätsSpital ZürichZürichSwitzerland

Personalised recommendations